Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.41M | 74.68M | 43.69M | 64.60M | 59.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.41M | 74.68M | 43.69M | 64.60M | 59.79M |
| Cost of Revenue | 495.15M | 546.22M | 547.14M | 498.07M | 432.40M |
| Gross Profit | -428.74M | -471.54M | -503.45M | -433.47M | -372.61M |
| SG&A Expenses | 165.05M | 185.10M | 220.12M | 216.25M | 201.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 660.19M | 731.33M | 767.25M | 714.31M | 633.82M |
| Operating Income | -593.78M | -656.65M | -723.57M | -649.72M | -574.03M |
| Income Before Tax | -564.36M | -644.89M | -715.69M | -649.12M | -575.28M |
| Income Tax Expenses | -4.58M | -135.00K | -148.00K | 16.00K | -507.00K |
| Earnings from Continuing Operations | -559.78 | -644.76 | -715.54 | -649.13 | -574.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -559.78M | -644.76M | -715.54M | -649.13M | -574.78M |
| EBIT | -593.78M | -656.65M | -723.57M | -649.72M | -574.03M |
| EBITDA | -509.74M | -572.95M | -646.39M | -586.39M | -525.59M |
| EPS Basic | -1.20 | -1.48 | -1.81 | -1.79 | -1.78 |
| Normalized Basic EPS | -0.77 | -0.94 | -1.13 | -1.12 | -1.11 |
| EPS Diluted | -1.20 | -1.48 | -1.81 | -1.79 | -1.78 |
| Normalized Diluted EPS | -0.77 | -0.94 | -1.13 | -1.12 | -1.11 |
| Average Basic Shares Outstanding | 1.92B | 1.79B | 1.60B | 1.44B | 1.26B |
| Average Diluted Shares Outstanding | 1.92B | 1.79B | 1.60B | 1.44B | 1.26B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |